PL320922A1 - Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes - Google Patents

Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes

Info

Publication number
PL320922A1
PL320922A1 PL95320922A PL32092295A PL320922A1 PL 320922 A1 PL320922 A1 PL 320922A1 PL 95320922 A PL95320922 A PL 95320922A PL 32092295 A PL32092295 A PL 32092295A PL 320922 A1 PL320922 A1 PL 320922A1
Authority
PL
Poland
Prior art keywords
somulating
mhc
molecules
prevention
bonding
Prior art date
Application number
PL95320922A
Other languages
English (en)
Inventor
Roger Pascal Lauener
Original Assignee
Om Lab Sa
Deutsche Om Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Lab Sa, Deutsche Om Arzneimittel Gmbh filed Critical Om Lab Sa
Publication of PL320922A1 publication Critical patent/PL320922A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
PL95320922A 1994-12-23 1995-12-27 Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes PL320922A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203755 1994-12-23
PCT/EP1995/005164 WO1996020215A2 (fr) 1994-12-23 1995-12-27 Utilisation de molecules se fixant a cnh-ii et/ou simulant cnh-ii dans la prevention et/ou le traitement des etats inflammatoires

Publications (1)

Publication Number Publication Date
PL320922A1 true PL320922A1 (en) 1997-11-10

Family

ID=8217495

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95320922A PL320922A1 (en) 1994-12-23 1995-12-27 Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes

Country Status (11)

Country Link
EP (1) EP0800534A2 (fr)
JP (1) JPH10511652A (fr)
CN (1) CN1171117A (fr)
AU (1) AU4347696A (fr)
BR (1) BR9510554A (fr)
CA (1) CA2208233A1 (fr)
CZ (1) CZ186897A3 (fr)
HU (1) HUT77468A (fr)
PL (1) PL320922A1 (fr)
SK (1) SK80697A3 (fr)
WO (1) WO1996020215A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840835A (en) * 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
US5817757A (en) * 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
WO1997035991A1 (fr) 1996-03-28 1997-10-02 The Johns Hopkins University Analogues solubles heterodimeres divalents et multivalents de proteines
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
EP0893507A1 (fr) * 1997-07-25 1999-01-27 Institut Gustave Roussy Utilisation de ligands de MHC classe II (CD4 et LAG-3) comme adjuvants pour la vaccination de LAG-3 dans le traitement du cancer
WO2003064472A2 (fr) * 2002-01-28 2003-08-07 Aimsco Limited Traitement
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
CA2452986C (fr) * 2001-07-02 2011-11-01 Aimsco Limited Utilisation d'un serum polyclonal anti-hiv de chevre comme agent theerapeutique
ES2232273B1 (es) * 2003-03-21 2006-07-16 Jose Manuel Fernandez-Real Lemos Nuevas aplicaciones terapeuticas de la glucoproteina cd14s.
EP1628530B8 (fr) * 2003-05-15 2012-08-01 Genentech, Inc. Procedes et compositions pour la prevention et le traitement de la sepsie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068790B1 (fr) * 1981-06-25 1986-02-26 The Board Of Trustees Of The Leland Stanford Junior University Méthode immunothérapeutique allèle spécifique et forme de dosage
GB8310403D0 (en) * 1983-04-18 1983-05-25 Mach B F Cotransformed mouse cells
JPS6225994A (ja) * 1985-05-30 1987-02-03 ジエネテイツク　システムズ　コ−ポレイシヨン Ｈｌａタイプ分け用モノクロ−ナル抗体
JPS63275526A (ja) * 1987-05-03 1988-11-14 Hiroshi Okajima Ｈｉｖウイルス中和抗体
FR2658197B1 (fr) * 1990-02-14 1992-05-22 Inst Nat Sante Rech Med Anticorps monoclonaux restreints reconnaissant un peptide associe a un antigene du complexe majeur d'histocompatibilite - applications au diagnostic et au traitement.
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
WO1993010220A1 (fr) * 1991-11-19 1993-05-27 Anergen, Inc. Molecules solubles du complexe majeur d'histocompatibilite et leurs utilisations
WO1993019772A1 (fr) * 1992-04-06 1993-10-14 North Shore University Hospital Research Corporation Nouvelle therapie permettant de traiter la septicemie a l'aide d'une forme soluble de l'antigene myelomonocytique cd14 recombine
AU674891B2 (en) * 1992-10-15 1997-01-16 Toray Industries, Inc. Process for producing major histocompatibility antigen class II protein and material having the same immobilized thereon
WO1994028025A1 (fr) * 1993-05-28 1994-12-08 The Scripps Research Institute Procedes et compositions d'inhibition de l'activation des cellules induites par cd14
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies

Also Published As

Publication number Publication date
WO1996020215A3 (fr) 1996-10-10
JPH10511652A (ja) 1998-11-10
CN1171117A (zh) 1998-01-21
BR9510554A (pt) 1999-06-29
CZ186897A3 (cs) 1998-03-18
CA2208233A1 (fr) 1996-07-04
SK80697A3 (en) 1997-12-10
WO1996020215A2 (fr) 1996-07-04
HUT77468A (hu) 1998-05-28
AU4347696A (en) 1996-07-19
EP0800534A2 (fr) 1997-10-15

Similar Documents

Publication Publication Date Title
IL117993A0 (en) Modified anti-icam-1 antibodies and their use in the treatment of inflammation
PL327312A1 (en) Tricyclic amides useful in inhibiting action of g protecin and in treatment of poliferation-type diseases
EP0963219A4 (fr) Manipulations de stress nitrosant et oxydatif dans le traitement d'une maladie
HUP9774641A2 (en) Gel for treatment of skin diseases and for disinfection of the skin
HUP9802662A3 (en) Substituted liposaccharides useful in the treatment and prevention of endotoxemia
FI950587A0 (fi) Endotoksiinimyrkytyksen ennaltaehkäisyssä ja hoidossa käyttökelpoisia menetelmiä
EP0924983A4 (fr) S(-)-tolterodine pour le traitement des troubles urinaires et gastro-intestinaux
PL320922A1 (en) Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes
EP0719791A3 (fr) Médicaments pour le traitement de la restenose et de la sclérose artérielle
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
GB2314273B (en) The use of TCET in the prophylaxis and treatment of allergies
IL119459A0 (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
IL116142A0 (en) Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
NO954175D0 (no) Anvendelse av vWF-inneholdende konsentrater som kombinasjonsterapi ved antitrombotika og fibrinolytika terapi
ZA958558B (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
PL330797A1 (en) Derivatives of piperidinacetic acid and their application in treating thrombotic disorders
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
EP1009433A4 (fr) Composition therapeutique et procede de traitement
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory
EP0893123A4 (fr) Moyen de traitement preventif et curatif de pathologies liees a differentes formes de vieillissement de l'organisme
EP0696055A3 (fr) Assemblages électroniques et procédés de traitement
AU3705697A (en) Proendothelin and hemoglobin in the treatment of acute hemorrhage
GB9419906D0 (en) Bnezoic amide retinoids for use in the treatment of skin diseases and cancer
AUPM932194A0 (en) Encapsulated substances and their use in the treatment of animals
AU1554295A (en) Method for treatment and prevention of disease in animals